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In-flight allergic emergencies
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Abstract
Allergic and hypersensitivity reactions such as anaphylaxis and asthma exacerbations may occur during air travel.
Although the exact incidence of in-flight asthma and allergic emergencies is not known, we have concerns that this
subject has not received the attention it warrants. There is a need to provide passengers at risk and airlines with the
necessary measures to prevent and manage these emergencies. A review of the epidemiology, management and
approaches to prevention of allergic and asthma emergencies during air travel is presented with the goal of increasing
awareness about these important, potentially preventable medical events.
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Background
About 2.75 billion passengers are transported worldwide
by airlines every year. Many of these people will have
pre-existing long-term conditions – including asthma
and/or allergy – which put them at risk of an in-flight
medical emergency. In a smaller minority of people,
these conditions may develop for the first time (i.e. inci-
dent cases) while in flight. It is expected that by 2030,
half of all aircraft passengers will be over 50 years of age
[1]. Up to 44,000 in-flight medical emergencies occur
each year [2], and data suggest that about 17% of such
cases are transferred to a hospital, with 4% resulting in
hospitalization or death.
Systemic allergic reactions (SAR) (a serious systemic al-
lergic reaction is defined as anaphylaxis) and asthma exac-
erbations (AE) may occur during air travel. We have
concerns that to date, these have not received sufficient at-
tention from passengers, airlines, and the medical com-
munity. In view of the potentially avoidable morbidity and
mortality, a review about the epidemiology, management
and prevention of allergic and asthma emergencies during
air travel is needed to increase awareness about these re-
actions and how to prevent and treat them. Likewise,
travel for the allergic and asthmatic passenger poses a
number of problems, in particular for those with a history
of a food-induced SAR or who have asthma. Patients may
experience, among other, fear of suffering an allergic
reaction or AE, problems regarding which medications to
carry on board, how to use them, or not receiving appro-
priate attention when seeking support from airline
personnel about their potential needs [3].
The frequency of these reactions among susceptible
passengers is unknown; however, data from peanut aller-
gic individuals indicate that approximately 9% of them
have experienced some sort of allergic reaction during
flights [4, 5].
Medical emergencies during air travel
In-flight medical emergencies occur in 1 per 11,000 pas-
sengers [6] or 1 in every 604 flights [2]. A number of
reasons are proposed to explain the incidence of medical
and allergic events during air travel, and those are sum-
marized in Table 1. The most common in-flight medical
events include syncope, gastrointestinal and cardiac
problems [2, 7, 8].
Alterations in passenger cabin during flight:
implications of physiological changes during air
travel to allergic and hypersensitivity diseases
There are two major concerns about allergic and respira-
tory diseases when traveling by air. The first is related to
the concentration of oxygen in the cabin. While in flight,
the cabin pressure is equivalent to an altitude of 6000 to
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8000 ft, exposing passengers to a partial pressure of arterial
oxygen of 60 mm Hg compared to 75 to 100 mm Hg at sea
level. Thus, the partial pressure of oxygen in the cabin air
at cruising altitude is 25–30% lower than at sea level. A
slight fall in oxygen blood saturation occurs, ranging from
92 to 95%, followed by compensatory hyperventilation and
tachycardia [9]. These physical alterations may affect pas-
sengers who have cardiac, respiratory or hematologic
(anemia) diseases, theoretically increasing the risk of exac-
erbations of allergic and hypersensitivity reactions such as
anaphylaxis.
These pressure changes can also result in “blocked
ears or sinuses” or, occasionally, barotitis or barosinusi-
tis. These conditions can usually be prevented by yawn-
ing, chewing gum during the flight, and by using a
sympathomimetic nasal spray such as oxymetazoline be-
fore ascent and descent.
The dry cabin atmosphere (with humidity 6–18%) can
also irritate the mucosal membranes of the mouth and
upper respiratory tract. Likewise, dehydration can occur,
especially in a passenger taking a diuretic. Therefore,
drinking plenty of extra fluids is recommended during
flight [10].
Asthma and allergic reactions
Allergic reactions account for an estimated 2–4% of
medical problems on board commercial airliners
(Table 2) [5, 11–13]. Buehrle and Gabler observed that
“allergy” was the 7th most common cause of in-flight
medical problems between 2002 and 2007, ranging from
1.5 to 2.5% [1]. During the same period asthmatic events
were 14th in frequency (0.6 to 3.2%).
Some authors propose that an AE is the most com-
mon, and potentially the most life-threatening condition
reported by major airlines. According to Dowdall’s study,
serious allergic reactions rarely occur. Respiratory events
were the 5th cause of aircraft medical conditions,
whereas allergic diseases, including urticaria, angio-
edema, additional forms of acute dermatitis, AE, and
SAR were the 11th most common [6]. SAR in airplanes
are most commonly triggered by foods (peanuts, tree
nuts, and seafood) or medications. Very rarely these are
triggered by insect stings or an insecticide spray [14].
There are reports of passengers having experienced
idiopathic anaphylaxis while in flight, administering self-
injected epinephrine (adrenaline) in the lavatory, and
not notifying the flight attendant (Greenberger P, per-
sonal communication). There are also reports of attacks
that have necessitated plane diversion to the closest
airport.
Other publications report that allergic emergencies are
responsible for 2.2% of all medical problems and result
in 4.5% of aircraft diversions [2]. Allergic reactions were
the 7th most frequent cause of medical events, and der-
matologic manifestations, including skin rashes, the 9th
most common cause in Baltszek’s study [11].
An article by Nable et al. on in-flight medical emer-
gencies did not discuss allergic conditions or SAR, al-
though it did mention a 12% incidence of “respiratory”
reactions [8]. This prompted Casale and Lemanske to
submit a letter to The New England Journal of Medicine
highlighting the need to consider “anaphylaxis” as a re-
action likely to occur during flights [15].
The lack of recognition of allergic reactions as an im-
portant cause of medical events during air travel could
be due to the fact that they are rare, or because they are
under-recognized, or diagnosed and not reported, since
methods to report such reactions are different and not
standardized [16, 17]. This is an area that therefore war-
rants further study. As previously stated, passengers
often do not report medical problems during flight [5].
In-flight treatment of allergic emergencies and
asthma
Treating medical emergencies during flight is a major
challenge and air travel is an important concern for sub-
jects with asthma and a history of a SAR.
The resources to treat allergic emergencies are some-
what limited. In the United States, the Federal Aviation
Administration requires the inclusion of epinephrine in
medical kits carried on board [18]. These emergency med-
ical kits typically contain the following medications [19]:
Table 1 Rick factors for medical and allergic events during air
travel
An increase of passenger’s age
Flight stress and anxiety, including
increased security procedures
Disruption of routine
Changes in the cabin environment
(temperature, humidity, air pressure)
Decreased seat space
Flight delays
Alcohol/drug intake
Longer flights
Altered circadian rhythm
Jet lag
Pre-existing medical conditions
Table 2 Prevalence of in-flight allergic reactions
Authors (year of publication) Prevalence (%) Reference
Szmajer et al. (2001) [13] 2.4 13
Delaune et al. (2003) [12] 2.8 12
Baltsezk (2008) [11] 3.7 11
Sand et al. (2012) [16] 2.2 17
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– Aqueous epinephrine (adrenaline) 1:10000 and
1:1000 dilution.
– Albuterol (salbutamol) for nebulization.
– Bronchodilator aerosol inhaler.
– Cortisol (hydrocortisone).
– Antihistamines tablets and injectable (commonly
diphenhydramine).
A recommendation from this World Allergy
Organization (WAO) expert group for in-flight treat-
ment of a SAR and AE is:
a) For AE, inhaled bronchodilator and oxygen.
Consider an oral, intramuscular or intravenous
corticosteroid for moderate to severe symptoms and
intramuscular epinephrine for severe symptoms.
b) For mild, moderate, and severe SAR, intramuscular
epinephrine 0.01 mg/kg up to 0.5 mg of 1:1000
solution IM in the anterior lateral thigh. Repeat as
necessary.
Prevention
Food-induced SAR are increasingly being observed in
many parts of the world. Strategies to reduce the risk of
a SAR while traveling should begin during the early
planning of the plane trip. Advice from their treating
physician or allergist/immunologist should be obtained
about preventive measures to be implemented before or
during the flight. Likewise, a treatment plan should be
instituted in case there is an inadvertent contact with a
known allergen, i.e., a peanut [20–25].
Greenberger and Lieberman propose that subjects with
idiopathic anaphylaxis not travel within a week of a previ-
ous episode and recommend the administration for an
adult of prednisone 40–60 mg and an H1 antihistamine
by mouth each morning for 1 week before travel. This can
help reduce the frequency and severity of episodes [26]. If
the flight is longer than 1 week after an episode of idio-
pathic anaphylaxis, empiric therapy should be initiated
and continued to reduce the likelihood of an attack while
in flight. For example, the passenger can be converted to
alternate day prednisone.
Medical departments of major airlines can also be con-
sulted about specific questions and recommendations for
air flights on individual carriers. Physicians on board
should be contacted immediately by the airline crew
for any emergency, including allergic emergencies, to
determine what treatment should be instituted and if
the plane should be diverted to the nearest airport. In
addition to medical kits on board and special training
of the crew on the management of medical emergen-
cies, airlines may have remote access to medical ser-
vices which can monitor and give instructions for the
Table 3 Measures that reduce the risk of an in-flight reaction to
peanut and tree nutsa
1. Passengers requesting any kind of special accommodation
(e.g., peanut/tree nut snacks not be distributed, announcement to not
eat items with peanut/tree nut, request special peanut/tree nut-free
meal, buffer zone, pre-board, request to sit in a certain seat/zone).
2. Peanut/tree nut-free meals.
3. Wiping of tray tables
4. Avoidance of airline pillows or blankets
5. Buffer zones around which peanut or nut products cannot be
consumed
6. Request other passengers not to consume peanut/tree nut-containing
products
7. Announcement that passengers do not eat peanut/tree nut
containing goods
8. Not consuming airline-provided food
aModified from reference [28]
Table 4 Airline policies for allergic passengers (Data from 13 air
carriers) a
Number of airlines
Pre-boarding arrangements
• Request a food “buffer zone” 5
• No “buffer zone” 3
• Request “allergen-free meal” 1
• Pre-boarding to wipe down seats
and table trays
Yes 4
No 1
• Buffer zone for fragrance sensitivity 2
• Announcements to inform customers
there is a peanut or tree-nut allergic
passenger on board or that peanut
products will not be served
Yes 4
No 7
Free snack policy on peanut/nut/sesame
• Serving peanuts Yes 2
No 11
• Serving nuts and sesameaw Yes 8
No 1
• First class warmed nuts 3
Gluten-free meals Yes 11
No 1
Lactose-free meals 1
Shellfish served Yes 4
No 3
Fish served Yes 6
No 1
Buffer zones for passengers allergic to pets 5
a In general air lines cannot guarantee an entirely peanut-free environment.
Modified from reference [30]
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best treatment until the plane arrives at a location
where the passenger can be adequately treated.
Measures to avoid peanut and tree nut exposure for
peanut and tree nut allergic individuals have resulted in
lower odds of in-flight SAR from these foods (Table 3)
[27, 28]. Since these measures may be difficult to imple-
ment, can cause discomfort for some passengers, and re-
sult in higher costs of travel, airlines and some travelers
might be reluctant to implement them.
Airline policies on allergy
Many airline carriers have devised strategies to prevent
SAR and AE during travel (Table 4). However, there are
no standardized measures to do so and each carrier has
its own recommendations. Retrieving first-hand infor-
mation about SAR and AE is difficult [29]. A summary
of proposed airline policies is presented in Table 5 [30].
Conclusions
As greater numbers of people fly, the number of AE and
SAR are likely to increase during flights in the future.
Therefore, passengers at risk should be aware of the ne-
cessary measures to prevent and manage these emergen-
cies. It is also vitally important that airlines are prepared
to deal with these diseases by providing the necessary
strategies to decrease the incidence of SAR and AE. They
also should have the necessary means to treat these reac-
tions when and if they occur. There is a clear opportunity
for airlines to work alongside allergists/immunologists to
implement evidence-based recommendations to prevent
allergic reactions during flight, especially SAR.
Abbreviations
AE: Asthma exacerbation; SAR: Systemic allergic reaction; WAO: World Allergy
Organization
Acknowledgements
This is a product of the Anaphylaxis Committee of the World Allergy
Organization. The authors thank the Board of Directors for approval and
support of the paper.
Funding
Not applicable.
Availability of data and materials
Not applicable.
Authors’ contributions
MSB drafted the manuscript. All authors contributed to the conception of
the review and revising it critically for important intellectual content. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Consent for publication was granted by all authors.
Ethics approval and consent to participate
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Allergy and Clinical Immunology Department, Centro Médico Docente La
Trinidad, Caracas, Venezuela. 2Allergy Section, Department of Internal
Medicine, Hospital Universitari Vall d’Hebron, Barcelona, Spain. 3Allergy
Research Group, Institut de Recerca Vall d’Hebron, Universitat Autònoma de
Barcelona, Barcelona, Spain. 4Allergie-Centrum-Charité, Klinik für
Dermatologie, Venerologie und Allergologie, Campus Charité Mitte,
Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. 5Division of
Allergy and Immunology, Department of Internal Medicine, University of
South Florida Morsani College of Medicine, Tampa, FL, USA. 6Allergy and
Respiratory Research Group, Usher Institute of Population Health Sciences
and Informatics, The University of Edinburgh, Edinburgh, UK. 7Division of
Allergy-Immunology, Department of Medicine, Northwestern University
Feinberg School of Medicine, Chicago, IL, USA. 8Department of Allergy and
Immunology, Hospital Quironsalud Bizkaia, Bizkaia, Spain. 9Department of
Allergy, Clinical Research Center for Allergy and Rheumatology, Sagamihara
National Hospital, Kanagawa, Japan. 10Pediatric Allergy & Immunology Unit,
Children’s Hospital, Ain Shams University, Cairo, Egypt. 11Department of
Pediatric Allergy & Immunology, Emory University School of Medicine,
Atlanta Allergy & Asthma, Atlanta, USA. 12Division of Medicine, Academy of
Medicine of Rio de Janeiro, Rio de Janeiro, Brazil. 13Division of Allergy and
Clinical Immunology, Department of Medicine, Quillen College of Medicine
and Center for Excellence for Inflammation, Infectious Disease and Immunity,
East Tennessee State University, Johnson City, TN, USA. 14Hospital Sírio
Libanês, São Paulo, Brazil. 15University Hospital of Montpellier, Montpellier,
and Sorbonne Universités, Paris, France. 16Department of Rheumatology,
Allergy and Immunology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng,
Singapore. 17Clínica El Avila, 6a.transversal Urb. Altamira, piso 8, consultorio
803, Caracas 1060, Venezuela.
Received: 19 December 2016 Accepted: 23 March 2017
References
1. Buehrle E, Gabler A. Notfallmedizin in flugzeng: erste hilfe über den wolken.
Dtsch Arztebl. 2005;102:338–42.
2. Peterson DC, Martin-Gill C, Guyette FX. Outcomes of medical emergencies
on commercial airline flights. N Engl J Med. 2013;368:2075–83.
3. Barnett J, Botting N, Gowland MH, Lucas JS. The strategies that peanut and
nut-allergic consumers employ to remain safe when travelling abroad. Clin
Transl Allergy. 2012;2:12.
4. Dowdall N. “Is there a doctor on the aircraft?” Top 10 in-flight medical
emergencies. Br Med J. 2000;321:1336–7.
5. Comstock SS, DeMera R, Vega LC, Boren EJ, Deane S, Haapanen LA, Teuber
SS. Allergic reactions to peanuts, tree nuts, and seeds aboard commercial
airliners. Ann Allergy Asthma Immunol. 2008;101:51–6.
6. Sicherer SH, Furlong TJ, DeSimone J, Sampson HA. Self-reported allergic
reactions to peanut on commercial airliners. J Allergy Clin Immunol. 1999;
104:186–9.
Table 5 Recommendations to prevent and manage in-flight
allergic events
• Promote the prevention of allergic diseases via passenger education
• Medical consultation for high-risk passengers before traveling
• Train and re-train aircrews
• Promote general preventive measures during the flight: hydration,
food allergen avoidance (especially peanuts, tree nuts, other foods, as
necessary)
• Provide an appropriate place for furry pets away from subjects with
pet allergy
• Provide for sufficient quantities of appropriate medications:
epinephrine (adrenaline), β2 agonists for inhalation and nebulization,
oral and injectable corticosteroids and antihistamines
• Oxygen
Sánchez-Borges et al. World Allergy Organization Journal  (2017) 10:15 Page 4 of 5
7. Sand M, Bechara F-G, Sand D, Mann B. Surgical and medical emergencies
on board European aircraft: A retrospective study of 10189 cases. Crit Care.
2009;13:R3.
8. Nable JV, Tupe CL, Gehle BD, Brady WJ. In-flight medical emergencies
during commercial travel. N Engl J Med. 2015;373:939–45.
9. American Medical Association Commission on Emergency Medical Services.
Medical aspects of transportation aboard commercial aircraft. J Am Med
Assoc. 1982;217:1007–11.
10. Goodwin T. In-flight medical emergencies: An overview. Br Med J. 2000;
321:1338–41.
11. Baltsezk S. Clinic in the air? A retrospective study of medical emergency
calls from a major international airline. J Travel Med. 2008;15:391–4.
12. Delaune EF, Lucas RH, Illig P. In-flight medical events and aircraft diversions:
One airline’s experience. Aviat Space Environ Med. 2003;74:62–8.
13. Szmajer M, Rodriguez P, Sauval P, Charetteur MP, Derossi A, Carli P. Medical
Assistance during commercial airline flights: Analysis of 11 years experience
of the Paris Emergency Service (SARIN) between 1989 and 1999.
Resuscitation. 2001;50:147–51.
14. Vanden Driessche KSJ, Sow A, Van Gompel A, Vandeurzen K. Anaphylaxis in
an airplane after insecticide spraying. J Travel Med. 2010;17:427–9.
15. Casale TB, Lemanske RF. In-flight medical emergencies. N Engl J Med. 2016;
374:291–2.
16. Sand M, Morrosch S, Sand D, Altmeyer P, Bechara FG. Medical emergencies
on board commercial airlines: Is documentation as expected? Crit Care.
2012;16:R42.
17. Ruskin KJ. In-flight medical emergencies: Time for a registry? Crit Care.
2009;13:121.
18. Federal Aviation Administration (FAA), DOT. Emergency Medical Equipment:
Final rule. Fed Regist. 2001;66:19028–46.
19. Graf J, Stüben U, Pump S. In-flight medical emergencies. Dtsch Arztebl Int.
2012;109:591–602.
20. Jackson KD, Howie LD, Akinbami LJ. Trends in allergic conditions among
children. United States, 1997–2011. NHCS data brief No. 121. National
Center for Health Statistics.: Hyattsville; 2013.
21. Ansotegui A, Sánchez-Borges M, Cardona V. Current Trends in Prevalence
and Mortality of Anaphylaxis. Curr Treat Options Allergy. 2016 (in press).
22. Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N, Garcez T,
Pumphrey R, Boyle RJ. Increase in anaphylaxis-related hospitalizations but
no increase in fatalities: an analysis of United Kingdom national anaphylaxis
data, 1992–2012. J Allergy Clin Immunol. 2015;135:956–63.
23. Nocerino R, Leone L, Cosenza L, Berni Canani R. Increasing rate of
hospitalizations for food-induced anaphylaxis in Italian children: An
analysis of the Italian Ministry of Health database. J Allergy Clin
Immunol. 2015;135:833–5.e3.
24. Rudders SA, Arias SA, Camargo Jr CA. Trends in hospitalizations for food-
induced anaphylaxis in US children, 2000–2009. J Allergy Clin Immunol.
2014;134(4):960–2.e3.
25. Mullins RJ, Dear KB, Tang ML. Time trends in Australian hospital
anaphylaxis admissions in 1998–1999 to 2011–2012. J Allergy Clin
Immunol. 2015;136:367–75.
26. Greenberger PA, Lieberman P. Idiopathic anaphylaxis. J Allergy Clin
Immunol Pract. 2014;2:243–50.
27. Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA, Plaut M,
Cooper SF, Fenton MJ, Arshad SH, Bahna SL, Beck LA, Byrd-Bredbenner C,
Camargo Jr CA, Eichenfield L, Furuta GT, Hanifin JM, Jones C, Kraft M, Levy
BD, Lieberman P, Luccioli S, McCall KM, Schneider LC, Simon RA, Simons FE,
Teach SJ, Yawn BP, Schwaninger JM. Guidelines for the diagnosis and
management of food allergy in the United States: Report of NIAID-
sponsored Expert Panel. J Allergy Clin Immunol. 2010;126:S1–S58.
28. Greenhawt M, Macgillivray F, Batty G, Said M, Weiss C. International study of
risk-mitigating factors and in-flight allergic reactions to peanut and tree nut.
J Allergy Clin Immunol Pract. 2013;1:186–94.
29. Shehata Y, Sheikh A. In-flight anaphylaxis emergencies: lessons gained from
attempting a questionnaire pilot study. Prim Care Respir J. 2007;16:321.
30. Van Evra J, Bennet P, Wicker A. Allergic Living handy chart on the allergy
policies of 13 major air carriers. Allergic Living magazine. Updated March
2016. Allergicliving.com. http://allergicliving.com/2010/08/30/comparing-
airlines/. Accessed 18 Dec 2016.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sánchez-Borges et al. World Allergy Organization Journal  (2017) 10:15 Page 5 of 5
